{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:19:50Z","timestamp":1792181990445,"version":"4.4.0"},"reference-count":56,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/mol.0b013e3283613a55","type":"journal-article","created":{"date-parts":[[2013,4,16]],"date-time":"2013-04-16T11:31:41Z","timestamp":1366111901000},"page":"227-232","source":"Crossref","is-referenced-by-count":30,"title":["Ezetimibe and bile acid sequestrants"],"prefix":"10.1097","volume":"24","author":[{"given":"Patrick","family":"Couture","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Lamarche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20211004","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOL.0b013e32813fa2e2","article-title":"Intestinal cholesterol transport proteins: an update and beyond.","volume":"18","author":"Levy","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"R2-8-20211004","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MOL.0b013e32834f0ef3","article-title":"Bile acid sequestrants: more than simple resins.","volume":"23","author":"Out","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"R3-8-20211004","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1194\/jlr.M027359","article-title":"Ezetimibe blocks the internalization of NPC1L1 and cholesterol in mouse small intestine.","volume":"53","author":"Xie","year":"2012","journal-title":"J Lipid Res"},{"key":"R4-8-20211004","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1194\/jlr.M900024-JLR200","article-title":"ABCA1 plays no role in the centripetal movement of cholesterol from peripheral tissues to the liver and intestine in the mouse.","volume":"50","author":"Xie","year":"2009","journal-title":"J Lipid Res"},{"key":"R5-8-20211004","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0022-2275(20)37999-2","article-title":"Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat.","volume":"24","author":"Spady","year":"1983","journal-title":"J Lipid Res"},{"key":"R6-8-20211004","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1073\/pnas.80.11.3499","article-title":"Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster.","volume":"80","author":"Spady","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R7-8-20211004","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1172\/JCI112066","article-title":"Receptor-independent low density lipoprotein transport in the rat in vivo. Quantitation, characterization, and metabolic consequences.","volume":"76","author":"Spady","year":"1985","journal-title":"J Clin Invest"},{"key":"R8-8-20211004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"R9-8-20211004","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1172\/JCI20978","article-title":"Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis.","volume":"113","author":"Engelking","year":"2004","journal-title":"J Clin Invest"},{"key":"R10-8-20211004","doi-asserted-by":"crossref","first-page":"12354","DOI":"10.1073\/pnas.94.23.12354","article-title":"Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver.","volume":"94","author":"Shimomura","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R11-8-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/jm030283g","article-title":"The discovery of ezetimibe: a view from outside the receptor.","volume":"47","author":"Clader","year":"2004","journal-title":"J Med Chem"},{"key":"R12-8-20211004","doi-asserted-by":"crossref","first-page":"8132","DOI":"10.1073\/pnas.0500269102","article-title":"The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).","volume":"102","author":"Garcia-Calvo","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R13-8-20211004","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1194\/jlr.M027599","article-title":"Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes.","volume":"53","author":"Engelking","year":"2012","journal-title":"J Lipid Res"},{"key":"R14-8-20211004","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1194\/jlr.M600439-JLR200","article-title":"The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin.","volume":"48","author":"Telford","year":"2007","journal-title":"J Lipid Res"},{"key":"R15-8-20211004","doi-asserted-by":"crossref","first-page":"G813","DOI":"10.1152\/ajpgi.90372.2008","article-title":"Inhibiting intestinal NPC1L1 activity prevents diet-induced increase in biliary cholesterol in Golden Syrian hamsters.","volume":"295","author":"Valasek","year":"2008","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R16-8-20211004","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ajcn\/43.1.92","article-title":"Serum plant sterols and their relation to cholesterol absorption.","volume":"43","author":"Tilvis","year":"1986","journal-title":"Am J Clin Nutr"},{"key":"R17-8-20211004","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s11745-000-0616-9","article-title":"Deuterium uptake and plasma cholesterol precursor levels correspond as methods for measurement of endogenous cholesterol synthesis in hypercholesterolemic women.","volume":"35","author":"Matthan","year":"2000","journal-title":"Lipids"},{"key":"R18-8-20211004","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0735-1097(00)00527-1","article-title":"Independent association of serum squalene and noncholesterol sterols with coronary artery disease in postmenopausal women.","volume":"35","author":"Rajaratnam","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R19-8-20211004","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/01.ATV.17.10.1910","article-title":"Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.","volume":"17","author":"Cuchel","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R20-8-20211004","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/BF00185608","article-title":"Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia.","volume":"71","author":"Parhofer","year":"1993","journal-title":"Clin Investig"},{"key":"R21-8-20211004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2337\/diabetes.52.3.803","article-title":"Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.","volume":"52","author":"Watts","year":"2003","journal-title":"Diabetes"},{"key":"R22-8-20211004","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1194\/jlr.P800061-JLR200","article-title":"Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.","volume":"50","author":"Tremblay","year":"2009","journal-title":"J Lipid Res"},{"key":"R23-8-20211004","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"R24-8-20211004","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia.","volume":"40","author":"Davidson","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"R25-8-20211004","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1463-1326.2011.01383.x","article-title":"Lipid-altering efficacy and safety profile of combination therapy with ezetimibestatin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials.","volume":"13","author":"Leiter","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"R26-8-20211004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1159\/000332436","article-title":"Effect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndrome.","volume":"21","author":"Kotani","year":"2012","journal-title":"Med Princ Pract"},{"key":"R27-8-20211004","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.atherosclerosis.2011.04.019","article-title":"Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction.","volume":"217","author":"Yunoki","year":"2011","journal-title":"Atherosclerosis"},{"key":"R28-8-20211004","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2362.2009.02163.x","article-title":"Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.","volume":"39","author":"Masuda","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"R29-8-20211004","doi-asserted-by":"crossref","first-page":"914","DOI":"10.5551\/jat.4929","article-title":"Molecular mechanisms of ezetimibe-induced attenuation of postprandial hypertriglyceridemia.","volume":"17","author":"Sandoval","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"R30-8-20211004","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/1074248411399762","article-title":"Effect of atorvastatin monotherapy and low-dose atorvastatinezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia.","volume":"17","author":"Lee","year":"2012","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"R31-8-20211004","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.atherosclerosis.2011.03.012","article-title":"Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.","volume":"217","author":"Bozzetto","year":"2011","journal-title":"Atherosclerosis"},{"key":"R32-8-20211004","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.2337\/dc09-1765","article-title":"Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.","volume":"33","author":"Chan","year":"2010","journal-title":"Diabetes Care"},{"key":"R33-8-20211004","first-page":"94","article-title":"Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism.","volume":"78","author":"Grundy","year":"1971","journal-title":"J Lab Clin Med"},{"key":"R34-8-20211004","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/hep.23408","article-title":"Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice.","volume":"51","author":"Herrema","year":"2010","journal-title":"Hepatology"},{"key":"R35-8-20211004","first-page":"779","article-title":"Colesevelam HCl: a nonsystemic lipid-altering drug.","volume":"4","author":"Bays","year":"2003","journal-title":"Expert Opin Pharmacother"},{"key":"R36-8-20211004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/HJR.0b013e32831215db","article-title":"Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol.","volume":"16","author":"Corsini","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"R37-8-20211004","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1023\/A:1007831418308","article-title":"Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent.","volume":"14","author":"Donovan","year":"2000","journal-title":"Cardiovasc Drugs Ther"},{"key":"R38-8-20211004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ecl.2008.11.007","article-title":"Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.","volume":"38","author":"Hou","year":"2009","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R39-8-20211004","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects.","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"key":"R40-8-20211004","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4065\/76.10.971","article-title":"Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial.","volume":"76","author":"Insull","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"R41-8-20211004","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.atherosclerosis.2005.05.032","article-title":"Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia.","volume":"185","author":"Rosenson","year":"2006","journal-title":"Atherosclerosis"},{"key":"R42-8-20211004","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjcard.2006.03.043","article-title":"Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia.","volume":"98","author":"Devaraj","year":"2006","journal-title":"Am J Cardiol"},{"key":"R43-8-20211004","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1007\/s10620-005-2765-8","article-title":"Effects of colesevelam HC1 on sterol and bile acid excretion in patients with type IIa hypercholesterolemia.","volume":"50","author":"Donovan","year":"2005","journal-title":"Dig Dis Sci"},{"key":"R44-8-20211004","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","article-title":"Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review.","volume":"99","author":"Insull","year":"2006","journal-title":"South Med J"},{"key":"R45-8-20211004","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1172\/JCI21025","article-title":"Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c.","volume":"113","author":"Watanabe","year":"2004","journal-title":"J Clin Invest"},{"key":"R46-8-20211004","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","article-title":"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.","volume":"125","author":"Claudel","year":"2003","journal-title":"Gastroenterology"},{"key":"R47-8-20211004","first-page":"1135","article-title":"The farnesoid X receptor: a novel drug target Expert Opin Investig D","volume":"13","author":"Claudel","year":"2004","journal-title":"rugs"},{"key":"R48-8-20211004","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacl.2011.01.005","article-title":"A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia.","volume":"5","author":"Davidson","year":"2011","journal-title":"J Clin Lipidol"},{"key":"R49-8-20211004","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/clc.4960240610","article-title":"Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia.","volume":"24","author":"Davidson","year":"2001","journal-title":"Clin Cardiol"},{"key":"R50-8-20211004","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"R51-8-20211004","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med"},{"key":"R52-8-20211004","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1185\/030079906X148436","article-title":"Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.","volume":"22","author":"Bays","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R53-8-20211004","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1507\/endocrj.K05-098","article-title":"Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia.","volume":"54","author":"Yamakawa","year":"2007","journal-title":"Endocr J"},{"key":"R54-8-20211004","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-121-6-199409150-00004","article-title":"Cholestyramine therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial.","volume":"121","author":"Garg","year":"1994","journal-title":"Ann Intern Med"},{"key":"R55-8-20211004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jacl.2012.05.005","article-title":"Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitus.","volume":"6","author":"Goldberg","year":"2012","journal-title":"J Clin Lipidol"},{"key":"R56-8-20211004","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2337\/dc11-2050","article-title":"Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and beta-cell function.","volume":"35","author":"Marina","year":"2012","journal-title":"Diabetes Care"}],"container-title":["Current Opinion in Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T22:24:30Z","timestamp":1633299870000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00041433-201306000-00008"}},"subtitle":["impact on lipoprotein metabolism and beyond"],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mol.0b013e3283613a55","relation":{},"ISSN":["0957-9672"],"issn-type":[{"value":"0957-9672","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}